Jacques Epelbaum, de l’équipe BIOADAPT, a co-publié l’article
Vidal JS, Hanaon O, Funalot B, Brunel N, Viollet C, Rigaud AS, Seux ML Le Bouc Y, Epelbaum J & Duron E. 2016 Low serum insulin-like growth factor-I predicts cognitive decline in Alzheimer’s disease. Journal of Alzheimer’s Disease DOI: 10.3233/JAD-15162
The relationship between the insulin-like growth factor-I (IGF-I) system and Alzheimer’s disease (AD) is mostly based on transversal studies. It remains, however, to demonstrate whether IGF-I is associated with cognitive decline over time in AD.
The objective of the study was to analyze the course of cognitive decline of AD subjects over a 24-month period in relation to serum IGF-I and insulin-like growth factor binding protein-3 (IGFBP-3) measured at baseline.
Data are from the SIGAL follow-up study. IGF-I and IGFBP-3 were measured in AD subjects who performed a Mini-Mental State Examination (MMSE) every 6 months for 2 years. MMSE course was analyzed using a mixed model with random intercept and slope function.
Among the 200 AD participants, 146 (mean age = 81.1 (standard deviation (SD) = 5.9) years, 62.6% of women) had at least one follow-up visit. Mean IGF-I at baseline was 147.8 (74.2) ng/mL. Hundred forty-six participants (62.6% ) had at least one follow-up visit. Mean MMSE was 21.7 (4.7) and dropped on average by 2.28 points per year. MMSE decline was steeper among participants with lower IGF-I. For each decrease of 1 SD of IGF-I, subjects lost an additional 0.63 points per year in MMSE, e.g., participants with IGF-I level of 74 ng/mL lost 2.91 MMSE points per year whereas participants with IGF-I of 222 ng/mL lost 1.65 MMSE points per year. There was no association between IGFBP-3 and cognitive decline.
Lower baseline serum IGF-I was associated with faster cognitive decline in AD over a 2-year period.